Curevac announces proposed public offering of common shares

TÜbingen, germany / boston, ma / accesswire / february 7, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), announced today that it intends to offer $200 million of its common shares in an underwritten public offering.
CVAC Ratings Summary
CVAC Quant Ranking